1
|
Shenjere P, Chasty R, Chaturvedi A, Dennis MW, Ong A, Wiseman DH, Menasce LP. E-Cadherin Expression in Blastic Plasmacytoid Dendritic Cell Neoplasms: An Unrecognized Finding and Potential Diagnostic Pitfall. Int J Surg Pathol 2020; 29:289-293. [PMID: 32608312 DOI: 10.1177/1066896920938130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
E-cadherin is expressed in hematopoietic erythroid precursors, but to our knowledge, its expression in blastic plasmacytoid dendritic cell neoplasm (BPDCN) has not been described. We report a case of BPDCN showing strong expression of E-cadherin, arising in a patient with history of primary myelofibrosis. Four more cases of BPDCN tested all showed strong expression of E-cadherin. Lack of awareness of this pattern of expression may lead to erroneous diagnosis of acute erythroid leukemia. It is increasingly becoming important to correctly identify this group of neoplasms, as approved new anti-CD123-targeted therapies are becoming available.
Collapse
Affiliation(s)
- Patrick Shenjere
- Department of Histopathology, 5294The Christie NHS Foundation Trust, Manchester, UK
| | - Richard Chasty
- Department of Haematology, The Christie NHS Foundation Trust, Manchester, UK
| | - Anshuman Chaturvedi
- Department of Histopathology, 5294The Christie NHS Foundation Trust, Manchester, UK
| | - Michael W Dennis
- Department of Haematology, The Christie NHS Foundation Trust, Manchester, UK
| | - Angelia Ong
- Department of Histopathology, 5294The Christie NHS Foundation Trust, Manchester, UK
| | - Daniel H Wiseman
- Department of Haematology, The Christie NHS Foundation Trust, Manchester, UK.,The University of Manchester, Manchester, UK
| | - Lia P Menasce
- Department of Histopathology, 5294The Christie NHS Foundation Trust, Manchester, UK
| |
Collapse
|
2
|
Guolo F, Minetto P, Clavio M, Marcolin R, Miglino M, Passannante M, Caviglia F, Ballerini F, Tedone E, Kunkl A, Mangerini R, Contini P, Colombo N, Cagnetta A, Cea M, Carminati E, Pugliese G, Gobbi M, Lemoli RM. Prognostic relevance of a blastic plasmacytoid dendritic cell neoplasm-like immunophenotype in cytogenetically normal acute myeloid leukemia patients. Leuk Lymphoma 2020; 61:1695-1701. [PMID: 32186422 DOI: 10.1080/10428194.2020.1737685] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a poor prognosis myeloid malignancy characterized by an atypical phenotype (CD123+, CD56+, and CD4+). We reported that BPDCN-like phenotype (CD123+ and either CD56+ or CD4+ or both) confers poor prognosis to acute myeloblastic leukemia (AML) patients with mutated NPM1. Here, we evaluated the incidence and the prognostic relevance of BPDCN-like phenotype in cytogenetically normal AML (CN-AML) patients. From 2006 to 2016, 83 young (age <60 yrs), consecutive, CN-AML patients underwent intensive treatment. Fifteen patients (18%) showed a BPDCN-like phenotype with no difference between NPM1-mutated (mut) and NPM1-wt patients. It did not significantly affect survival neither in the whole cohort, nor in NPM1-wt patients. However, as reported, it conferred a dismal prognosis in NPM1-mut AML (p < 0.001), irrespectively of the mutational status for FLT3-ITD. In conclusion we show that BPDCN-like phenotype displays a negative prognostic relevance only in NPM1-mutated AML.
Collapse
Affiliation(s)
- Fabio Guolo
- Department of Oncology and Hematology, Ospedale Policlinico San Martino, Genoa, Italy.,Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, Genoa, Italy
| | - Paola Minetto
- Department of Oncology and Hematology, Ospedale Policlinico San Martino, Genoa, Italy.,Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, Genoa, Italy
| | - Marino Clavio
- Department of Oncology and Hematology, Ospedale Policlinico San Martino, Genoa, Italy.,Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, Genoa, Italy
| | - Riccardo Marcolin
- Department of Oncology and Hematology, Ospedale Policlinico San Martino, Genoa, Italy.,Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, Genoa, Italy
| | - Maurizio Miglino
- Department of Oncology and Hematology, Ospedale Policlinico San Martino, Genoa, Italy.,Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, Genoa, Italy
| | - Monica Passannante
- Department of Oncology and Hematology, Ospedale Policlinico San Martino, Genoa, Italy.,Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, Genoa, Italy
| | - Fabrizio Caviglia
- Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, Genoa, Italy
| | - Filippo Ballerini
- Department of Oncology and Hematology, Ospedale Policlinico San Martino, Genoa, Italy.,Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, Genoa, Italy
| | - Elisabetta Tedone
- Department of Oncology and Hematology, Ospedale Policlinico San Martino, Genoa, Italy.,Clinical Flow Cytometry Unit, Department of Pathology, Ospedale Policlinico San Martino, Genoa, Italy
| | - Annalisa Kunkl
- Department of Oncology and Hematology, Ospedale Policlinico San Martino, Genoa, Italy.,Clinical Flow Cytometry Unit, Department of Pathology, Ospedale Policlinico San Martino, Genoa, Italy
| | - Rosa Mangerini
- Department of Oncology and Hematology, Ospedale Policlinico San Martino, Genoa, Italy.,Clinical Flow Cytometry Unit, Department of Pathology, Ospedale Policlinico San Martino, Genoa, Italy
| | - Paola Contini
- Clinical Flow Cytometry Unit, Department of Pathology, Ospedale Policlinico San Martino, Genoa, Italy
| | - Nicoletta Colombo
- Department of Oncology and Hematology, Ospedale Policlinico San Martino, Genoa, Italy.,Clinical Flow Cytometry Unit, Department of Pathology, Ospedale Policlinico San Martino, Genoa, Italy
| | - Antonia Cagnetta
- Department of Oncology and Hematology, Ospedale Policlinico San Martino, Genoa, Italy
| | - Michele Cea
- Department of Oncology and Hematology, Ospedale Policlinico San Martino, Genoa, Italy.,Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, Genoa, Italy
| | - Enrico Carminati
- Department of Oncology and Hematology, Ospedale Policlinico San Martino, Genoa, Italy.,Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, Genoa, Italy
| | - Girolamo Pugliese
- Department of Oncology and Hematology, Ospedale Policlinico San Martino, Genoa, Italy.,Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, Genoa, Italy
| | - Marco Gobbi
- Department of Oncology and Hematology, Ospedale Policlinico San Martino, Genoa, Italy.,Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, Genoa, Italy
| | - Roberto Massimo Lemoli
- Department of Oncology and Hematology, Ospedale Policlinico San Martino, Genoa, Italy.,Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, Genoa, Italy
| |
Collapse
|